BACKGROUND: The anterior chamber has been shown by pharmacokinetic studies to represent a sanctuary never achieving a tumoricidal dose with the present administration routes, such as systemic, intra-arterial, or intravitreal injections. METHOD: A novel intracameral chemotherapy technique is described to control aqueous seeding in a pilot unilateral group E retinoblastoma case with primary aqueous seeding. Anterior segment toxicity was carefully monitored. RESULTS: Control of the retinal tumor and vitreous seeding was achieved by intra-arterial and intravitreal chemotherapies. Sterilization of the aqueous was achieved after a first cycle of 7 melphalan injections in the anterior chamber, but relapse was noted 3.5 months later. This relapse was finally controlled with a second cycle of 6 intracameral injections targeting the posterior chamber. Corneal endothelial cell density remained stable over the injection period. Heterochromia and a progressive cataract developed, which required cataract surgery. At 5 years' follow-up, the patient is tumor free with normal vision (20/20 in both eyes), full binocularity, and no metastasis. CONCLUSIONS: The present bicameral injection technique appears to be safe and effective with limited toxicity. Melphalan-induced side effects were noted on the iris and lens but with no impact on the final visual function.
BACKGROUND: The anterior chamber has been shown by pharmacokinetic studies to represent a sanctuary never achieving a tumoricidal dose with the present administration routes, such as systemic, intra-arterial, or intravitreal injections. METHOD: A novel intracameral chemotherapy technique is described to control aqueous seeding in a pilot unilateral group E retinoblastoma case with primary aqueous seeding. Anterior segment toxicity was carefully monitored. RESULTS: Control of the retinal tumor and vitreous seeding was achieved by intra-arterial and intravitreal chemotherapies. Sterilization of the aqueous was achieved after a first cycle of 7 melphalan injections in the anterior chamber, but relapse was noted 3.5 months later. This relapse was finally controlled with a second cycle of 6 intracameral injections targeting the posterior chamber. Corneal endothelial cell density remained stable over the injection period. Heterochromia and a progressive cataract developed, which required cataract surgery. At 5 years' follow-up, the patient is tumor free with normal vision (20/20 in both eyes), full binocularity, and no metastasis. CONCLUSIONS: The present bicameral injection technique appears to be safe and effective with limited toxicity. Melphalan-induced side effects were noted on the iris and lens but with no impact on the final visual function.
Entities:
Keywords:
Anterior chamber fluid; Aqueous seeding; Chemotherapy; Intracameral chemotherapy; Intravitreal injection; Melphalan; Pathology of the anterior segment; Retinoblastoma
Authors: B G Haik; S A Dunleavy; C Cooke; R M Ellsworth; D H Abramson; M E Smith; Z A Karcioglu Journal: Ophthalmology Date: 1987-04 Impact factor: 12.079
Authors: Swathi Kaliki; Carol L Shields; Duangnate Rojanaporn; Saad Al-Dahmash; John P McLaughlin; Jerry A Shields; Ralph C Eagle Journal: Ophthalmology Date: 2013-02-08 Impact factor: 12.079
Authors: Lorena V Baroni; Claudia Sampor; Adriana Fandiño; Veronica Solernou; Graciela Demirdjian; Maria T G de Davila; Guillermo L Chantada Journal: J Pediatr Hematol Oncol Date: 2014-11 Impact factor: 1.289
Authors: Carol L Shields; Fariba Ghassemi; Samuray Tuncer; Archana Thangappan; Jerry A Shields Journal: Ophthalmology Date: 2008-10-29 Impact factor: 12.079